Lanlan Wang
Hui Wang
Yamei Yuan
Weidong Ye*- Anhui University of Chinese Medicine, Hefei, China
Asthma is a complex chronic inflammatory airway disease, whose pathogenesis involves interactions among multiple cell types and molecular pathways. Pulmonary neuroendocrine cells (PNECs), rare epithelial cells in the lungs, have recently gained attention as pulmonary sensors. PNECs detect environmental signals and regulate pulmonary immune responses and physiological functions by releasing neuropeptides and neurotransmitters. Aberrant activation of PNECs is implicated in various respiratory diseases, including asthma, where they interact significantly with other cell types, such as type 2 innate lymphoid cells (ILC2s), goblet cells, and eosinophils. Recent studies have highlighted the potential of targeting PNEC-related pathways for developing novel anti-inflammatory drugs and identifying biomarkers to evaluate drug efficacy and toxicity in asthma. Exploring asthma pathogenesis through the functional characteristics of PNECs and their interactions with other cells could have potential clinical value in diagnosing and treating of asthma.
1 Introduction
Asthma is a common chronic respiratory disease with prevalence rates that vary significantly across different countries and regions. Despite considerable advances in asthma management, the prevalence, incidence, and mortality rates continue to rise, imposing a substantial burden on individuals and public health systems (Zhang L. et al., 2025).
Asthma is characterized by inflammatory responses, airway remodeling, and airway hyperresponsiveness (Song et al., 2025). Airway epithelial and smooth muscle cells are pivotal to its pathogenesis. Airway epithelial cells serve as the primary barrier against inhaled pathogens and particles, triggering inflammation and mucus production, both of which contribute to airway obstruction. Another significant cause of airway obstruction is bronchoconstriction mediated by airway smooth muscle cells (Raby et al., 2023). Asthma does not present as a single symptom but rather encompasses multiple syndromes with distinct etiologies, pathophysiological mechanisms, clinical manifestations, and therapeutic responses. Its causes are diverse: allergic asthma is triggered by allergens (e.g., house dust mites, pollen, pet dander) and is typically associated with elevated specific IgE levels; non-allergic asthma is unrelated to allergies and can be triggered by infection, air pollution, or occupational exposures. Other forms include exercise-induced asthma, drug-induced asthma and obesity-related asthma (Imayama et al., 2024). The pathophysiology of asthma is multifaceted. Type 2 inflammatory asthma is characterized by Th2 cells, ILC2s, eosinophils and IgE, typically linked to allergic asthma. Non-type 2 inflammatory asthma involves neutrophils, Th1/Th17 cells, or paucigranulocytic patterns, frequently associated with more severe disease and corticosteroid resistance (Matucci et al., 2021; Fuhlbrigge and Sharma, 2025). Clinical manifestations vary in severity, ranging from mild intermittent episodes to severe persistent symptoms. Attack frequency also varies considerably, from occasional to frequent occurrences. Lung function impairment differs in severity, potentially resulting in significant airflow limitation in severe cases. Asthma management emphasises individualised treatment. For instance, some patients respond well to inhaled corticosteroids (ICS), whereas others exhibit steroid resistance. Responses to specific biologics (e.g., anti-IgE, anti-IL-5 therapies) also vary markedly among asthma subtypes (D’Amato et al., 2025; Pelaia et al., 2020). Consequently, asthma research necessitates greater precision.
Although PNECs constitute only approximately 0.5% of the lung epithelium, they play a crucial role in respiratory health and disease (Candeli and Dayton, 2024). As airway sensors, PNECs detect environmental stimuli and modulate immune cell activity by releasing neuropeptides such as calcitonin gene-related peptide (CGRP) and gamma-aminobutyric acid (GABA), This triggers pulmonary immune responses, influencing the symptoms and progression of various lung diseases. Particularly in allergic asthma, PNECs amplify immune reactions by stimulating ILC2s (Sui et al., 2018; (Branchfield et al., 2016). Furthermore, PNECs are critical in lung development and regeneration, with the ability to transdifferentiate into other cell types, such as Clara cells and ciliated cells, following lung injury (Candeli and Dayton, 2024). The role of PNECs in asthma involves complex intercellular interactions. Cells such as ILC2s, goblet cells, and eosinophils interact with PNECs to varying degrees, collectively influencing asthma pathogenesis and progression. Therefore, trageting PNECs for asthma treatment offers novel therapeutic avenues (Figure 1).
Figure 1. Conceptual Framework for Multi-cellular Interactions of PNEC-derived Mediators in Asthma (By Figdraw). Abbreviations: PNEC, Pulmonary neuroendocrine cell; CGRP, Calcitonin gene-related peptide: ILC2s,type 2 innate lymphoid cells; IL, Interleukin; Eos, Eosinophils; Al, Airway Inflammation; AR, Airway Remodelling; AHR, Airway Hyper-responsiveness; MBP, Major basic protein; EPO, Eosinophil Peroxidase; M2. Muscarinic Acetylcholine Receptor Type 2; ACh, Acetylcholine; 5-HT, Serotonin: DC, Dendritic Cell; Th2, T helper type 2 cell; PAH, Pulmonary Arterial Hypertension: GABA, Gamma-aminobutyric acid; STAT, Signal Transducer and Activator of Transcription; FOXA, Forkhead Box A; SPDEF,SAM Pointed Domain-containing ETS Transcription Factor; DEP, Depolarization: GC, Goblet cell; MUC, Mucin; SHH, Sonic Hedgehog; TGF-β1, Transforming Growth Factor Beta 1; COL1A1, Collagen Type I Alpha 1 Chain; MMP2, Matrix Metalloproteinase 2; ECs, Epithelial Cells; TSLP, Thymic stromal lymphopoietin; EETS, Eosinophil extracellular traps:SMO, Smoothened; GLI3, Glioma-Associated Oncogene Homolog 3: ATP, Adenosine Triphosphate; MEC, Myoepithelial Cell.
2 Overview of PNECs
PNECs exhibit distinctive distribution and morphology, with primary roles in chemosensation, immunoregulation, regeneration and repair, and neuromodulation. Crucial signalling pathways associated with PNECs include the Notch and Hedgehog pathways.
2.1 Distribution and morphology of PNECs
PNECs constitute a distinct epithelial cell type lining the airways of varying sizes, maintaining contact with sensory nerve fibers (Seeholzer and Julius, 2024). Within the airway epithelium, PNECs exist as solitary cells or small clusters, interspersed between the two primary airway epithelial cell types:secretory Clara cells and ciliated cells (Rawlins et al., 2009). Neuroepithelial bodies (NEBs) are cellular clusters consisting of PNEC aggregates (20–30 cells), bearing membrane receptors sensitive to numerous stimuli, including hypoxia and nicotine. Isolated PNECs typically exhibit a flask-shaped or elongated morphology. Under scanning electron microscopy, NEBs form crater-like depressions lined with microvilli, surrounded by non-ciliated cells with smooth surfaces at their periphery. Stereo-photmicroographs reveal that these surrounding cells project above the adjacent bronchioles mucosa (Noguchi et al., 2020; De Proost et al., 2008). NEBs have direct contact with the airway lumen and are exclusively located at airway bifurcations, whereas isolated PNECs or smaller clusters are scattered throughout the bronchial epithelium. This distribution pattern highlights their crucial role in pulmonary function and disease (Gilmour, 2015). and reflects their unique function as intrapulmonary sensors.
2.2 Primary functions of PNECs
2.2.1 Chemosensory function
PNECs rapidly detect changes in oxygen levels and respond to hypoxic environments, a capability seemingly linked to their distinct localization at airway bifurcations. During hypoxia, they express and secrete serotonin (5-hydroxytryptamine; 5-HT) (Fu et al., 2002), a monoamine neurotransmitter that induces pulmonary vasoconstriction. The localised hypoventilation observed in bronchoconstrictive asthma patients spatially correlates with reduced perfusion, a phenomenon attributed to hypoxic pulmonary vasoconstriction (HPV) (Kelly et al., 2017). Dense cisternae vesicles (DCVs) are present in the cytoplasm of NEB cells, storing neurotransmitters, amines, peptides, and other substances. Hypoxic conditions can trigger DCV degranulation, releasing these substances in response to environmental changes. Furthermore, NEBs express several essential proteins that collectively constitute the functional NADPH oxidase complex. under hypoxic conditions, K+ channels on PNECs close, whereas voltage-gated Ca2+ channel open, facilitating extracellular Ca2+influx and inducing Ca2+-dependent exocytosis of DCVs (Youngson et al., 1993). This suggests that NEBs may serve as hypoxia-sensitive airway chemical sensors in respiratory regulation.
PNECs can detect nicotine, which induces acute asthma attacks and promotes pulmonary edema, lung injury, and abnormal leukocytosi, thereby exerting detrimental effects on both pulmonary and systemic functions (Ahmad et al., 2019). Nicotine,an agonist of nicotinic acetylcholine receptors (nAChRs), and its nitrosamine derivative NNK can induce PNEC hyperplasia in asthma by upregulating α7-nicotinic acetylcholine receptors (α7-nAChR) in PNECs. These proliferated PNECs subsequently induce pulmonary hypertension through secretion of 5-HT (Schuller et al., 2003).
Beyond sensing hypoxia and nicotine stimulation, PNECs also respond to mechanical changes. Mechanical stretching stimulates PNECs to release 5-HT, thereby influencing lung development (Pan et al., 2006).
2.2.2 Immunomodulation
PNECs are neuroendocrine cells possessing dual neurosensory and endocrine functions (Xu et al., 2020). Using genetically engineered knockout mice, Branchfield et al. demonstrated that inactivation of the Roundabout gene in PNECs disrupts normal aggregation of and enhances neuropeptide production, triggering an elevated immune response. The sequence of events—elevated neuropeptide secretion from PNECs, increased immune cell infiltration, and lung architectural remodeling—indicates that PNECs, despite their scarcity, function as sensitive and effective variable resistors within the airway wall. They receive, interpret, and respond to environmental stimuli, initiating immune responses via neuropeptides, and thereby exert immunomodulatory effects (Branchfield et al., 2016).
Achaete-scute-like protein 1 (Ascl1), a basic helix-loop-helix transcription factor, serves as an early determinant of PNEC fate. Sui et al. generated mouse mutants lacking PNECs by inactivating Ascl1 in airway epithelium. Following allergen challenge, reduced secretion of PNEC-derived substances (such as CGRP and GABA), severe diminishment of goblet cell proliferation, decreased immune cell infiltration, and suppressed type 2 (allergic) immune responses were observed in Ascl1-mutant mice. Additionally, ILC2s, like PNECs, accumulate at airway branching points. Subsequent investigations revealed that stimulating mouse ILC2s with CGRP induces interleukin-5 (IL-5) production, whereas inactivation of the CGRP receptor gene Calcrl in ILC2s was attenuates their response to allergens. This indicates that CGRP, a product of PNECs, induces cytokine secretion in ILC2s. Thus, PNECs enhance ILC2s activity by secreting CGRP, thereby recruiting downstream immune cells. Whilst GABA does not induce cytokine secretion in ILC2s as CGRP does,allergen challenge in GABA-inactive knockout mice (Gad1CKO mice) showed reduced goblet cell proliferation. This indicates that GABA can promote goblet cell proliferation and increase mucus secretion. Further research demonstrated that instilling a mixture of CGRP and GABA in mouse mutants with specifically ablated PNECs (Ascl1CKO mice) restores both the immune cell infiltration and goblet cell proliferation. This demonstrates that CGRP and GABA are the primary molecular effectors through which PNECs exert their immune functions in vivo (Sui et al., 2018).
It should be noted that the current conclusions are primarily based on mouse experiments, and direct human evidence remains lacking. Although mouse models are powerful tools for studying asthma mechanisms, differences in PNEC distribution, abundance, and immune microenvironment between humans and mice may exist.
2.2.3 Regeneration and repair
PNECs play a pivotal role in lung regeneration and repair following injury. They not only self-renew but also differentiate into other cell types to support epithelial restoration. The stem cell function of PNECs is regulated by multiple genes, including the tumor suppressors Rb and P53, which inhibit excessive self-renewal. During airway injury, the Notch pathway is activated, initiating cellular deprogramming and migration to form large regenerative epithelial clonal patches that are essential for pulmonary environmental responses. It should be noted that not all PNECs exhibit stem cell activity; typically, only 2–4 cells per NEB possess reserve stem cell potential (Ouadah et al., 2019).
NEBs are considered a reserve niche for airway epithelial regeneration and contribute to local repair following Clara cell depletion. Reynolds et al., using an animal model of airway injury and repair, observed that epithelial regeneration after naphthalene-induced Clara cell ablation of preferentially occurred at airway branching points, resulting in the formation of new Clara cells. Expression of Clara cell secretory protein (CCSP) facilitated airway repair and NEB-associated proliferation, indicating that sustained regeneration is accompanied by NEB expansion. This suggests that the NEB microenvironment serves as an airway progenitor reservoir supporting focal epithelial regeneration (Reynolds et al., 2000a). NEBs constitute a highly dynamic structure that responds to chronic airway injury through PNEC proliferation. However, PNECs themselves function as a self-renewing progenitor population, and NEBs-associated Clara cells are not required for proliferative responses to chronic injury (Reynolds et al., 2000b).
2.2.4 Neuromodulation
PNECs lie in close proximity to neural and immune cells, forming neuroimmune modules that enable the lung to sense and respond to environmental cues. PNECs are innervated (Kuo and Krasnow, 2015; (Brouns et al., 2009) and may participate in neurosecretory processes within the mucosal bronchioles and bronchioles (Popko et al., 2020) forming synaptic contacts with afferent and efferent nerve fibers. NEBs can transmit neural impulses to the central nervous system, functioning as neuroreceptors that mediate axon reflex-driven local regulation (Cutz et al., 2013). Moninger et al. proposed that PNECs possess latent sensory capabilities linked to the vagus nerve and immune system. Submucosal glands (SMGs), which produce protective mucus, contain PNECs that detect succinate, an inflammatory metabolite in airway surface fluid. In response, release ATP to stimulate myoepithelial cell contraction, thereby promoting mucus expulsion onto the airway surface. While essential for host defence, excessive mucus secretion may aggravate pulmonary disease. Thus, PNEC-mediated activation of SMGs in response to inflammatory signals significantly contributes to respiratory host defense (Yu et al., 2022), (Chang et al., 2015), forming part of the immunomodulatory response to inflammation and infection.
PNECs are the only pulmonary epithelial cells with direct neuronal innervation and play an crucial role in airway-nerve communication through neural pathways and hormone release, with potential implications for neuroprotection in diseases such as asthma. By integrating neuronal and endocrine functions, PNECs secrete neuropeptides upon stimulation that travel via the vagus nerve to the brain, where they modulate brainstem respiratory centers (Branchfield et al., 2016). In exercise-induced asthma, PNECs can detect changes in airways osmotic pressure and temperature, triggering reflex parasympathetic activation and vagus nerve-mediated bronchoconstriction (Thakur et al., 2024).
2.3 Primary signalling pathways involving PNECs
2.3.1 Notch signalling pathway
The differentiation of PNECs is regulated by basic helix-loop-helix (bHLH) transcription factors such as Mash1 and Hes1. The Notch signaling pathway exerts a pivotal role in PNECs differentiation through regulation of Hes1 expression. Studies indicate that mice deficient in Mash1 exhibit an absence of PNECs, while those deficient in Hes1 display excessive PNEC proliferation. Thus, Mash1 serves as a marker for PNECs, whereas Hes1 is expressed primarily in non-neuroendocrine cells (Ito et al., 2003). Furthermore, immunohistochemical analysis detects Notch1, Notch2, and Notch3 in non-neuroendocrine cells, with Notch1 mRNA expression being dependent on Hes1 (Ito et al., 2000). These findings suggest that the balance between PNECs and non-neuroendocrine cell formation is tightly regulated by Notch signaling.
2.3.2 Hedgehog signalling pathway
The Hedgehog signaling pathway contributes to PNEC of differentiation and the development of small cell lung cancer (SCLC). Activation of this pathway occurs during lung injury repair and normal differentiation of neuroendocrine precursor cells (Watkins et al., 2003), promoting epithelial-to-goblet cell transformation (Xu et al., 2018). ICS primarily suppress lymphocyte and eosinophil activity but exert limited effects on upstream epithelial signalling pathways, such as Hedgehog signalling, and the neurosecretory functions of PNECs. This partially explains the ineffectiveness of ICS in preventing airway remodelling in certain patients. Consequently, targeting the Hedgehog pathway represents a promising strategy for early intervention in chronic airway diseases.
The Hedgehog signalling pathway is activated in the airways of children with allergic asthma. In eosinophilic asthma, PNECs activate Hedgehog signalling through secretion of ligands such as Sonic Hedgehog (SHH), promoting TGF-β1-mediated collagen (COL1A1) and MMP2 expression. Increased COL1A1 expression, partially mediated by the PTCH1–SMO–GLI axis of the Hedgehog pathway, contributes to airway fibrosis and remodelling. Thus, Hedgehog signalling represents a potential therapeutic target for chronic airway diseases, including asthma. GLI inhibitors (e.g., GANT61) suppress downstream fibrotic and inflammatory gene expression by targeting GLI1/2 transcription factors, reducing excessive extracellular matrix synthesis and deposition (Tam et al., 2022).
In neutrophilic asthma, the Hedgehog pathway facilitates Th17 cell differentiation via Smo and GLI3, dependent on the IL-6/STAT3 signalling axis, thereby upregulating inflammatory mediators such as IL-17A. This asthma phenotype often demonstrates glucocorticoid resistance. Experimental studies have shown that Smo and GLI3 are upregulated during in vitro Th17 polarisation and in vivo models of Th17-dominant asthma. Inhibition of Smo with small-molecule inhibitors or knockdown of GLI3 suppresses Th17 polarisation. Furthermore, inhibiting Smo affects the polarisation of not only Th17 cells but also Th1, Th2, and Treg cells. GLI3 directly interacts with IL-6 in T cells, inducing STAT3 phosphorylation and promoting Th17 cell differentiation; indeed, IL-6 is essential for GLI3-mediated regulation of Th17 polarisation. Additionally, clinical data have confirmed correlations between elevated GLI3 expression and increased levels of IL-17A and IL-6 in asthmatic children. These findings provide molecular insights into the interaction between Hedgehog signalling and Th17 differentiation, highlighting Smo and GLI3 as potential therapeutic targets for corticosteroid-resistant asthma driven by Th17 cells (Jin et al., 2024). Smo inhibitors (such as Vismodegib and Criptobanil) can reduce airway inflammation and remodelling by targeting the Hedgehog pathway, thereby alleviating various asthma phenotypes (Th2/Th17-type) (El-Baz et al., 2022).
3 Interaction between PNECs and immune cells
Direct or indirect interactions occur between PNECs and various immune cells, including ILC2s, goblet cells, and eosinophils. These cells, together with their interactions, play crucial roles in the pathogenesis and progression of eosinophilic asthma.
3.1 PNECs and ILC2s
3.1.1 ILC2s and asthma
ILC2s represent a key class of immune cells predominantly located in mucosal tissues. Capable of rapid responses to allergens and environmental stimuli, they play multiple roles in asthma pathogenesis. They induce airway inflammation by producing large quantities of type 2 cytokines, such as IL-5 and IL-13, thereby triggering eosinophilic inflammation and airway hyperresponsiveness. These cytokines promote airway remodeling and mucus secretion, ultimately leading to airway obstruction and exacerbated symptoms (Kabata et al., 2015). Furthermore, ILC2s compromise bronchial epithelial barrier integrity through IL-13 (Sugita et al., 2018). They also synergise with Th2 cells via direct and indirect interactions to orchestrate type 2 immune responses (Matsuyama et al., 2023), thus playing a pivotal role in the immunopathology of asthma.
3.1.2 Interactions between PNECs and ILC2s
During asthma development, PNECs stimulate ILC2s to produce IL-5 either through direct cell–cell contact or via secretion of the neuropeptide CGRP. These cytokines subsequently recruit downstream immune cells, amplifying the inflammatory cascade. Concurrently, ILC2s feedback-regulate PNEC activity by releasing cytokines. PNECs and ILC2s form neuroimmune modules at airway branching points, where they detect inhaled allergens and amplify these signals into robust pulmonary allergic responses. Environmental triggers, such as allergens, viral infections, and air pollution, may worsen asthma symptoms by activating the PNECs-ILC2s axis. This axis contributes to asthma pathogenesis and progression by promoting type 2 inflammation, enhancing airway hyperresponsiveness, and facilitating airway remodeling (Sui et al., 2018).
3.2 PNECs and goblet cells
3.2.1 Goblet cells and asthma
Goblet cells are a major epithelial cell type responsible for secreting mucus to protect and lubricate the airway surfaces. In asthma, goblet cell number and function undergo substantial alterations. Abnormal goblet cell proliferation, along with changes in mucin (MUC) storage and secretion, contributes to key pathological features, including excessive mucus production and airway obstruction. Goblet cell hyperplasia is a well-established hallmark of asthma (Fahy, 2002; Ordoñez et al., 2001). Cytokines such as IL-13 and IL-4 promote goblet cell transdifferentiation and proliferation through induction of Th2-type immune responses. These cytokines exacerbate airway narrowing and clinical symptoms by increasing mucus storage secretion through MUC gene upregulation (Sun et al., 2017; Sahnoon et al., 2025).
3.2.2 Interactions between PNECs and goblet cells
Interactions between PNECs and goblet cells in asthma largely involve the modulation of neurotransmission and immune signalling. PNECs regulate airway epithelial and immune cell activity by secreting molecules such as GABA and CGRP, thereby promoting the pathological airway changes.
PNECs are the primary source of GABA in the lung. GABA acts on airway epithelial cells via GABA_A and GABA_B receptors. Binding of GABA to GABA_A receptors activates Cl− channels, leading to cellular depolarisation and Cl− efflux, which promotes epithelial proliferation and differentiation into goblet cells. In asthma, expression of GABA_A and GABA_B receptor subtypes is elevated compared to healthy individuals. In a model of mucus-overproducing human bronchial epithelial cells, pharmacological blockade of GABA_A and GABA_B signaling reversed IL-13-mediated MUC5AC expression and goblet cell proliferation (Barrios et al., 2019). Further inhibition of GABA signalling reduced airway epithelial swelling, goblet cell hyperplasia, mucus secretion, and IL-13 levels simultaneously (Xiang et al., 2007). PNECs also enhance ILC2 activity by secreting CGRP, which promotes IL-13 production, activates the STAT6 signalling pathway, and upregulates GABA receptor expression. This synergises with GABA signalling to induce transcription factors SPDEF and FOXA3. SPDEF is a core driver of goblet cell differentiation, directly inducing mucin gene expression (e.g., MUC5AC) and promoting the goblet cell phenotype. FOXA3 similarly facilitates goblet cell differentiation, whereas FOXA2 is inhibited by IL-13; relieving this inhibition enhances goblet cell maturation and mucin production (Kimura et al., 2023). Thus, PNECs promote goblet cell proliferation and excessive mucus secretion through coordinated GABA and CGRP signalling, synergising with IL-13. Moreover, increased PNEC proliferation activates the GABAergic system, which enhances goblet cell proliferation and hypertrophy by suppressing the SMAD signalling pathway, thereby removing constraints on goblet cell differentiation (Piao et al., 2021; Feldman et al., 2019).
3.3 PNECs and eosinophils
3.3.1 Eosinophils and asthma
Eosinophils are granulocytes containing eosinophilic granules that play significant role in allergic diseases, especially allergic eosinophilic asthma. They participate in allergic inflammatory responses not only as important effector cells but also as antigen-presenting cells (Choi, 2021). The mechanism underlying eosinophil involvement in asthma include their activation and migration within the airways. Cytokines produced by Th2 cells (e.g., IL-5 and IL-13) and chemokines (e.g., eosinophil chemotactic factor) directly mediate eosinophil recruitment to the lungs (Possa et al., 2013).
Eosinophils may exacerbate bronchoconstriction through neuroimmune interactions, thereby influencing asthma pathogenesis (Mattes and Collison, 2020). Firstly, eosinophils increase airway sensory nerve density and enhance nerve sensitivity by lowering neuronal activation thresholds, promoting nerve growth, and altering neuropeptide expression, thus driving airway hyperresponsiveness and bronchoconstriction (Drake et al., 2018a). Secondly, M2 muscarinic receptors on parasympathetic nerves play a critical role in regulating acetylcholine release in airway cholinergic nerves (Ghosh et al., 2025). Normally, M2 receptors modulate airway contraction by inhibiting acetylcholine release; however, this feedback mechanism is impaired in asthma (Drake et al., 2018b). Eosinophils antagonize M2 receptors by releasing major basic proteins (MBPs) and peroxidase (EPO), which function as endogenous allosteric antagonists of M2 receptors, thereby impairing their inhibitory function (Costello et al., 1998), (Jacoby et al., 1993), This leads to increased acetylcholine release and bronchial hyperreactivity (Fryer et al., 1999). Eosinophils also significantly contribute to inflammatory responses and airway remodeling by releasing pro-inflammatory mediators, including cationic proteins, cytokines, and chemokines (McBrien and Menzies-Gow, 2017). Eosinophil programmed cell death, such as necroptosis, is closely linked to inflammation and airway remodeling in asthma (He et al., 2022).
3.3.2 Interactions between PNECs and eosinophils
Interactions between PNECs and eosinophils amplify allergic asthma responses at airway branching points via neuroimmune modules, which sense inhaled allergens and convert these stimuli into pulmonary immune responses.
Eosinophil extracellular traps (EETs), composed of DNA fibers and cytotoxic granulin proteins, are implicated in asthma pathogenesis (Choi et al., 2018), with excessive EET production potentially contributing to chronic inflammation and autoimmunity (Mukherjee et al., 2018). Thymic stromal lymphopoietin (TSLP), secreted by epithelial cells in response to environmental stimuli, activates cells of the innate and adaptive immune systems. Eosinophils respond to TSLP stimulation by producing EETs (Morshed et al., 2012), which in turn activate PNECs. PNEC activation further amplifies immune responses through secretion of neuropeptides and neurotransmitters, possibly via the CCDC25-ILK-PKCα-CRTC1 pathway (Lu et al., 2021).
4 Pathological mechanisms of PNECs in asthma
Asthma can be classified into eosinophilic (allergic), neutrophilic, mixed-cell, and oligocellular phenotypes. The mechanisms by which PNECs and their secreted neuropeptides and neurotransmitters function differ across asthma phenotypes and exhibit phenotype specificity. Mediators such as 5-HT, CGRP, and GABA are particularly crucial in allergic (type 2) asthma pathogenesis. CGRP and GABA respectively promote immune cell activation and goblet cell hyperplasia, exacerbating airway inflammation and mucus secretion. Thus, targeting PNECs and their signalling molecules represents a promising strategy for precision asthma therapies (Table 1).
Table 1. Summary of key signaling molecules, pathways, and targeted therapeutic strategies in asthma pathophysiology.
4.1 Inflammatory response
PNECs regulate inflammatory responses through the release of neuropeptides and neurotransmitters following allergen exposure. Neuropeptides (substance P [SP], neurokinin A [NKA], vasoactive intestinal peptide [VIP], CGRP, and nociceptin/orphanin FQ [N/OFQ]) and neurotransmitters ((5-HT and GABA) exhibit diverse roles: some are pro-inflammatory, others anti-inflammatory, and certain mediators may bidirectionally modulate inflammation (Pavón-Romero et al., 2021).
4.1.1 Neuropeptides
Substance P (SP) and neurokinin A (NKA) play central roles in airway inflammatory responses, primarily mediated through neurokinin-1 (NK-1R) and neurokinin-2 receptors (NK-2R) (Joos et al., 2000). SP exerts pro-inflammatory effects by binding to NK-1R on immune and epithelial cells. Asthma patients show heightened responsiveness to SP, with increased bronchial NK-1R expression (O'Connor et al., 2004; Li et al., 2022). NKA primarily mediates pro-inflammatory actions in asthma (Groneberg et al., 2004), although it can exhibit anti-inflammatory effects under specific conditions (Sumpter et al., 2014). Vasoactive intestinal peptide (VIP) is abundant in healthy lung of tissue (Onoue et al., 2007), modulating immune responses and exerting anti-inflammatory effects by interacting with specific receptors on immune cells (Misaka et al., 2010); thus, VIP functions as a potent anti-inflammatory mediator in asthma (Verma et al., 2017). Nociceptin/orphanin FQ (N/OFQ) may also demonstrate anti-inflammatory actions in severe asthma (D’Agostino et al., 2019).
CGRP can exert both pro-inflammatory and anti-inflammatory effects. The CGRP receptor consists of two components: a G protein-coupled receptor and a calcitonin gene-related peptide receptor-like (CLR) protein associated with receptor activity-modifying protein 1 (RAMP1). Studies indicate that the absence of the both receptors reduces inflammatory responses (Li et al., 2014). CGRP receptor antagonists suppress inflammation in allergic asthma by downregulating mouse ILC2s, supporting a pro-inflammatory role for CGRP (Ike et al., 2023). Conversely, in models such as acute lung injury, both endogenous and exogenous CGRP markedly attenuate inflammation, acting as key negative regulators of ILC2s activity to exert anti-inflammatory effects (Zhang R. et al., 2025). Clinically, the use of CGRP antagonists occasionally leads to inflammatory complications, suggesting that CGRP’s anti-inflammatory actions possess significant immunoregulatory value in vivo. These findings also highlight the complexity of CGRP-mediated immunomodulation. CGRP’s dual roles depend strongly on the tissue microenvironment, cell type, and signalling context, with its effects varying across experimental models and disease settings. Future studies must further elucidate its regulatory mechanisms and clinical implications.
4.1.2 Neurotransmitters
The role of 5-HT in asthma is complex, as it can promote inflammation via certain mechanisms while exerting anti-inflammatory effects through activation of receptors such as 5-HT2A (Flanagan et al., 2017; Nau et al., 2012; Flanagan et al., 2024).
GABA also displays duality in asthma, possessing both anti-inflammatory and pro-inflammatory properties depending on receptor subtype, cell type, inflammatory milieu, and specific regulatory pathways. GABA and its receptors, particularly GABA_A receptors, are expressed on multiple immune cells (e.g., T cells, macrophages). Upon activation, they inhibit the production of inflammatory cytokines such as IL-6 and TNF-α, thereby reducing airway inflammation. Studies show that electroacupuncture-activated GABA signalling significantly attenuates airway inflammation in asthmatic mice by inhibiting the TLR4/MyD88/NF-κB pathway, an effect reversed by GABA_A receptor antagonists (Gong et al., 2023). Knockout of the GABA_A receptor α4 subunit enhances pulmonary inflammation and airway hyperreactivity in mouse asthma models, demonstrating the anti-inflammatory role of GABAergic signalling. Orally administered GABA_A receptor agonists (e.g., MIDD0301) effectively alleviate airway hyperresponsiveness and inflammation in asthmatic mice without inducing significant immunosuppression (Zahn et al., 2019). Notably, different GABA_A receptor subtypes exhibit distinct functional profiles. Activation of subtypes such as α1, α4, and α5 suppresses inflammation, whereas α3 activation may correlate with pro-inflammatory responses (Yocum et al., 2017). Although GABA signalling has limited direct impact on mucus secretion, it amplifies pathological mucus overproduction in the presence of inflammatory mediators like IL-13. Under such conditions, GABA_A receptor antagonists may be used to reduce mucus secretion. GABA_B receptors, as G protein-coupled receptors, regulate cAMP signalling and may influence epithelial and immune cell behaviour through paracrine mechanisms. In inflammatory conditions such as viral pneumonia, GABA_B receptor antagonists can attenuate inflammation, whereas agonists may worsen asthma symptoms, underscoring the need for precise therapeutic selection (Shirey et al., 2023). Future clinical applications of GABA-related therapies should be tailored to patient phenotypes and underlying pathological characteristics.
4.2 Airway remodeling
Airway remodeling represents another major pathological feature of asthma, holding significance equal to inflammation in the disease’s aetiology. Structural alterations in asthma include epithelial disruption, subepithelial fibrosis, goblet cell hyperplasia or metaplasia, smooth muscle hypertrophy or hyperplasia, and increased vascularization (Banno et al., 2020).
4.2.1 Notch signalling
Studies demonstrate that following naphthalene-induced airway injury, rapid proliferation and hypertrophy of PNECs and NEBs occur during epithelial repair (Peake et al., 2000), indicating a significant role for PNECs in airway remodeling. Under conditions of airway injury, PNECs undergo transdifferentiation via activation of the Notch signaling pathway, thereby contributing to the regeneration of airway epithelial cells (Popko et al., 2020; Zhang et al., 2022). Notch signalling is a critical regulator of Ascl1, a transcription factor essential for PNEC formation and maintenance. Its inactivation can induce PNEC apoptosis through downregulation of Bcl2. Kim et al. demonstrated in mouse models that Notch signalling negatively regulates Ascl1 expression. Specifically, downregulation of Notch promotes PNEC proliferation, whereas Notch agonists suppress excessive proliferation, reducing airway reactivity and remodelling (Kim et al., 2025). Consequently, Notch agonists represent a promising therapeutic strategy to limit excessive PNEC proliferation and mitigate remodelling when combined with conventional asthma treatments.
4.2.2 Epithelial-mesenchymal transition (EMT)
EMT constitutes a key mechanism underlying airway remodelling in chronic asthma. IL-24 promotes EMT in human bronchial epithelial cells (BEAS-2B) through activation of STAT3-and ERK1/2-dependent pathways, whereas IL-37 reverses this process, highlighting the IL-24/IL-37 axis as a potential therapeutic target to inhibit EMT and reduce airway remodelling. IL-37 exerts potent anti-inflammatory effects on innate and adaptive immunity. In a house dust mite (HDM)-induced mouse asthma model, IL-37 reduced airway eosinophil infiltration and remodelling by inhibiting IL-24-mediated EMT via modulation of STAT3 and ERK1/2 signalling. These findings identify IL-24 as a novel therapeutic target and IL-37 as a promising therapeutic agent for severe asthma (Feng et al., 2022).
4.2.3 Rac1 signalling
Dilasser et al. demonstrated the potential role of Rac1 signalling in airway remodelling and airway smooth muscle cell (aSMC) proliferation in severe asthma, using human bronchial biopsies, cultured human aSMCs, and a severe allergic asthma mouse model sensitised to HDM. Pharmacological inhibition of Rac1 in vivo prevented airway remodelling associated with asthma, confirming Rac1 as a promising therapeutic target for severe asthma. Inhibiting Rac1-dependent signalling pathways concurrently reduced aSMC proliferation, airway hyperresponsiveness (AHR), and inflammation, presenting a novel approach to reverse airway remodelling and restore airway function in severe asthma patients. NSC23766, a Rac1 inhibitor, effectively mitigates airway remodelling with greater efficacy than some conventional therapies and minimal adverse effects (Dilasser et al., 2021).
4.2.4 Cathepsin C/K
In severe asthma (SA) and uncontrolled asthma (UA), increased secretion of Cathepsin C by airway epithelial cells activates the epithelial-mesenchymal transition unit (EMTU) via p38-mediated pathways, thereby promoting airway remodelling. Yuan et al. screened differentially expressed genes in epithelial cells from SA and UA patients using RNA sequencing and identified Cathepsin C. Validation confirmed increased Cathepsin C levels in induced sputum samples from asthma patients, positively correlating with disease severity and airway remodelling. Direct instillation of exogenous Cathepsin C induced airway remodelling, whereas genetic suppression of Cathepsin C inhibited EMTU activation and remodelling. Therefore, Cathepsin C represents a promising biomarker and therapeutic target for SA or UA. AZD7986, a potent Cathepsin C inhibitor, prevents airway remodelling and inflammation in HDM-induced asthma mouse models. Currently in Phase III clinical trials for non-cystic fibrosis bronchiectasis (NCFBE), AZD7986 demonstrated manageable dental and cutaneous side effects at certain doses, not impeding clinical advancement (Yuan et al., 2024).
Elevated airway epithelial secretion of Cathepsin K activates EMTU through PAR2-mediated pathways. Qin et al. detected increased Cathepsin K levels in induced sputum from asthma patients (mild-to-moderate asthma [MMA] and SA), identifying it as a potential biomarker for airway remodelling. Experimental studies demonstrated significantly increased Cathepsin K expression in airway epithelium correlating with airway remodelling severity in HDM-induced mouse asthma models. Targeted inhibition of Cathepsin K suppressed EMTU activation and alleviated airway remodelling. Odanacatib, a specific CTSK inhibitor, effectively inhibited EMTU activation both in vitro and in vivo (Qin et al., 2024). Although odanacatib shows promise in asthma animal models, clinical data in asthma remain unavailable. Given its known cardiovascular and cerebrovascular side effects, future development of asthma treatments targeting Cathepsin K must prioritise target specificity and systemic safety.
4.2.5 NLRP3 inflammasome
MiR-223-3p in mesenchymal stem cell-derived exosomes inhibits inflammation and remodelling via the NLRP3/ASC/Caspase-1/GSDMD pathway (Li and Yang, 2023). Stem cell-derived exosomes exhibit potent and targeted suppression of inflammation and remodelling. However, most studies remain limited to in vitro experiments and mouse models, with no available human clinical trial data. Moreover, optimal delivery routes (e.g., nebulisation, intravenous administration) and dosing strategies have yet to be systematically evaluated.
4.3 Airway hyperresponsiveness
Studies have shown that early respiratory exposure to arsenic exacerbates airway hyperresponsiveness in OVA-induced allergic asthma. Arsenic exposure further elevates 5-HT synthase levels and 5-HT content in the lungs of OVA-induced asthmatic mice. Upregulation of tryptophan hydroxylase (TPH)1 and TPH2,the two key 5-HT synthases, is markedly intensified in arsenic-exposed OVA-induced mice. LX1032, a specific TPH inhibitor, prevents the arsenic-induced exacerbation of airway hyperresponsiveness. These findings indicate that inhaled arsenic worsens airway hyperresponsiveness in OVA-induced allergic asthma by upregulating PNECs-derived 5-HT (Lu et al., 2025).
5 Therapeutic targets
5.1 Targeting PNEC secretions
Increased PNEC numbers and enlarged NEB aggregates in asthma patients, accompanied by heightened responses to allergens, suggest that PNECs represent a viable therapeutic target. Approaches aimed at inhibiting PNEC secretions such as CGRP and GABA may offer new treatment options. Studies show that HDM exposure induces CGRP release from PNECs, which can be blocked by protease-activated receptor 1 (PAR1) antagonists, highlighting CGRP as a potential therapeutic target (Mann-Nüttel et al., 2024). MIDD0301, a novel oral asthma therapy, reduces airway smooth muscle contraction and inflammation by targeting pulmonary GABA receptors without inducing systemic immunosuppression (Forkuo et al., 2018; Zahn et al., 2019). Futhan, a rapidly metabolised serine protease inhibitor, has been shown to reversibly inhibit the GABA_A receptors in A549 human alveolar epithelial cells (Chen et al., 2011) (Figure 2).
Figure 2. Schematic diagram of the PNEC-immune-neural network and its potential therapeutic targets. Abbreviations: SP, Substance P; NK-1R, Neurokinin-1 receptors; NKA, Neurokinin A; Neurokinin-2 receptors; VIP, Vasoactive intestinal peptide; N/OFQ Nociceptin/orphanin FQCGRP, Calcitonin gene-related peptide; CLR/PAMP1, Calcitonin Receptor-Like Receptor/Receptor Activity-Modifying Protein 1: Aprepitant, NK-1R antagonists: SR 48968, NK-2R antagonists; Aimegepant, CGRP receptor antagonists; 5-HT, Serotonin:5-HTZA, Serotonin Receptor 2A: TPH, Tryptophan hydroxylase; GABA,Gamma-aminobutyric acid: LX1032, TPH inhibitors: MIDD0301,GABA A receptor agonists miR-223-3P,microRNA-223-3p: NLRP3/ASC/Caspase-1, NOD-LRR-and Pyrin Domain-Containing Protein 3/Apoptosis-Associated Speck-Like Protein Containing a CARD/Cysteine-dependent Aspartate-Specific Protease-1; Notch, Neurogenic locus notch homolog protein; SHH, Sonic Hedgehog; PTCH1/SMO/GLI, Patched-1/Smoothened/Glioma-Associated Oncogene Homolog: STAT3, Signal Transducer and Activator of Transcription 3; ERK1/2, Extracellular Signal-Regulated Kinase 1/2; Rac1, Ras-related C3 botulinum toxin substrate 1: Cyclopamine, SMO inhibitors; GANT61, GLI inhibitors; NSC23766, Rac1 inhibitors:p38,p38 Mitogen-Activated Protein Kinase; EMTU, Epithelial-Mesenchymal Trophic Unit: PAR2, Protease-Activated Receptor 2; AZD7986, Cathpsin C inhibitor: Odanacatib, Cathepsin K inhibitor.
5.2 Interactions targeting PNECs with other cells
Targeting PNEC interactions with immune and epithelial cells, including the PNEC–ILC2 axis, PNEC–epithelial axis, and broader neuro-immune regulatory pathways, represents an emerging direction for novel asthma therapies, with several compounds demonstrating promising effects in animal models.
PNECs secrete CGRP to directly activate ILC2s, promoting the release of inflammatory mediators such as IL-5 and driving airway inflammation. Rimegepant, a CGRP receptor antagonist, effectively alleviates allergic asthma symptoms in mice by inhibiting the PNEC–CGRP–ILC2s pathway (Ike et al., 2023). PNEC-secreted GABA induces goblet cell hyperplasia and excessive mucus secretion—a key mechanism underlying airway remodelling and symptom exacerbation in asthma. GABA signalling inhibitors can block the PNEC–GABA–goblet cell axis by antagonising GABA_A or GABA_B receptors, thereby reducing mucus production (Thakur et al., 2024). PNECs also interact with neurons via the vagus nerve and TRPA1 pathways to regulate airway reactivity and inflammation. Targeting molecules such as TRPA1 and NT4 can disrupt neurogenic regulation of PNEC secretion, reducing excessive mucus production. Bronchial thermoplasty attenuates airway inflammation by disrupting the vagal ganglion TRPA1–PNEC axis through NRG1–ERBB signalling between PNECs and neighbouring cells (Feng et al., 2025).
6 Discussion
Asthma is a complex chronic inflammatory airway disease involving intricate interactions among various cells and molecules. PNECs have attracted increasing attention in asthma research due to their unique biological characteristics and extensive intercellular interactions. Current studies suggest that targeting PNECs could offer novel therapeutic approaches for asthma management. However, the precise regulatory mechanisms and their differential contributions to distinct asthma phenotypes require further investigation. Existing research primarily focuses on eosinophilic (allergic) asthma, whereas the specific roles and regulatory mechanisms of PNECs in neutrophilic (non-type 2) asthma remain underexplored. PNECs are implicated in various other diseases, including COPD and lung cancer. Targeting PNECs may induce non-specific adverse effects, necessitating vigilance regarding potential risks. PNECs participate not only in inflammatory responses but also in airway injury repair and regeneration. The functions of PNECs in airway epithelial regeneration, fibrosis, and interactions with stem and stromal cells remain largely unexplored. Multiple molecules secreted by PNECs exhibit overlapping functions; intervention at a single target may be compensated by alternative pathways, thereby compromising therapeutic efficacy. Additionally, the lack of effective functional testing systems for human-derived PNECs and large-scale clinical data has hindered the translation of fundamental discoveries into clinical applications. Interventions targeting PNECs have yet to advance into clinical evaluation, indicating a substantial translational gap.
This gap may be attributed to several factors. Firstly, the heterogeneity of PNECs across different airway compartments remains inadequately characterised, complicating target identification and the elucidation of underlying mechanisms. Secondly, the absence of reliable biomarkers impedes patient stratification and efficacy monitoring, as demonstrated by the lack of standardised detection methods for CGRP and GABA in exhaled breath condensate (EBC). Thirdly, the complex interactions through which environmental exposures (e.g., pollutants, cigarette smoke, and e-cigarettes) influence PNEC activation and downstream immune responses, coupled with significant population heterogeneity, further increase uncertainty in clinical translation. Moreover, PNECs constitute an extremely small fraction of the pulmonary epithelium, presenting significant challenges in isolation, purification, and in vitro culture. This limitation has restricted research involving human samples, with findings predominantly relying on animal models, thereby carrying inherent risks of species-specific differences. Existing studies are largely based on mouse or primate models; certain gene knockout or overexpression models may inadequately replicate human asthma’s complexity, necessitating cautious extrapolation. Current animal models and traditional 2D cell cultures inadequately replicate the complexity of the human PNEC–immune axis, lacking high-fidelity in vitro systems suitable for mechanistic exploration and drug screening.
To accelerate the clinical translation of therapies targeting the PNEC–immune axis, future research should employ single-cell sequencing and spatial omics technologies to systematically characterise the molecular features, distribution, and interactions of PNECs with immune cells across different airway regions. Single-cell sequencing has revealed multiple PNEC subtypes with distinct gene expression and functional characteristics under disease conditions. Future studies should clarify the specific roles of each subtype within different asthma phenotypes and their interactions with immune cells. Existing research indicates that PNECs amplify airway inflammatory responses by regulating ILC2s and goblet cells via neuropeptides (e.g., CGRP) and neurotransmitters (e.g., GABA). Future investigations should explore the bidirectional regulatory networks between PNECs and the nervous and immune systems, particularly focusing on interactions with the vagus nerve and Trpv1+ neurons, and their effects on airway hyperresponsiveness. Given the significantly elevated numbers and activity of PNECs in asthma patients, targeting molecules such as CGRP and GABA secreted by PNECs could serve as promising novel therapies. Future research should evaluate pharmacological interventions targeting PNEC-related signalling pathways and their efficacy across different asthma phenotypes. Detection methods for biomarkers (e.g., CGRP and GABA in EBC) require further standardisation, complemented by multi-omics approaches to identify novel PNEC-associated biomarkers for non-invasive diagnosis and treatment prediction. Systematic investigations are also necessary to clarify how environmental factors, including pollutants, cigarette smoke, and e-cigarettes, affect PNEC activation, secretion, and immune modulation, elucidating their roles in asthma susceptibility and progression. Additionally, organoid and 3D co-culture systems should be developed to reconstruct the PNEC–immune microenvironment. Combined with PNEC-specific inhibitors, these advanced models will facilitate in-depth mechanistic studies and robust drug screening, thereby enhancing translational potential. Advances in human-derived PNEC culture and organoid technologies now allow better simulation of human disease environments, thereby accelerating the translation of basic research into clinical applications.
In summary, clinical translation of strategies targeting the PNEC–immune axis urgently requires integrated advancement in fundamental and applied research. PNECs, as pivotal cells in asthma pathogenesis, hold significant research value due to their extensive intercellular interactions and unique neuroendocrine-immune functions. Future research should focus on their functional subtypes, neuro-immune regulatory networks, targeted therapies, and clinical translation. Concurrently, vigilance is required regarding model limitations, detection challenges, and potential adverse effects. While actively pursuing breakthroughs, technical limitations and clinical risks must be cautiously addressed to advance this field towards greater precision and personalisation. Progress in areas such as heterogeneity analysis, biomarker development, elucidation of environmental mechanisms, and high-fidelity in vitro modelling will establish a robust foundation for developing innovative therapies targeting the PNEC–immune axis.
Author contributions
LW: Writing – original draft. HW: Writing – review and editing. YY: Writing – review and editing. WY: Writing – review and editing. XF: Writing – review and editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. National Natural Science Foundation of China Youth Fund Project (82305187); National Natural Science Foundation of China Project (82575020); National Natural Science Foundation of China Project (82074401).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ahmad, S., Zafar, I., Mariappan, N., Husain, M., Wei, C. C., Vetal, N., et al. (2019). Acute pulmonary effects of aerosolized nicotine. Am. J. Physiology-Lung Cell. Mol. Physiology 316 (1), L94–L104. doi:10.1152/ajplung.00564.2017
Banno, A., Reddy, A. T., Lakshmi, S. P., and Reddy, R. C. (2020). Bidirectional interaction of airway epithelial remodeling and inflammation in asthma. Clin. Science 134 (9), 1063–1079. doi:10.1042/CS20191309
Barrios, J., Kho, A. T., Aven, L., Mitchel, J. A., Park, J. A., Randell, S. H., et al. (2019). Pulmonary neuroendocrine cells secrete γ-aminobutyric acid to induce goblet cell hyperplasia in primate models. Am. Journal Respiratory Cell Molecular Biology 60 (6), 687–694. doi:10.1165/rcmb.2018-0179OC
Branchfield, K., Nantie, L., Verheyden, J. M., Sui, P., Wienhold, M. D., and Sun, X. (2016). Pulmonary neuroendocrine cells function as airway sensors to control lung immune response. Science 351 (6274), 707–710. doi:10.1126/science.aad7969
Brouns, I., Oztay, F., Pintelon, I., De Proost, I., Lembrechts, R., Timmermans, J. P., et al. (2009). Neurochemical pattern of the complex innervation of neuroepithelial bodies in mouse lungs. Histochem. Cell Biology 131, 55–74. doi:10.1007/s00418-008-0495-7
Candeli, N., and Dayton, T. (2024). Investigating pulmonary neuroendocrine cells in human respiratory diseases with airway models. Dis. Models Mech. 17 (5), dmm050620. doi:10.1242/dmm.050620
Chang, R. B., Strochlic, D. E., Williams, E. K., Umans, B. D., and Liberles, S. D. (2015). Vagal sensory neuron subtypes that differentially control breathing. Cell 161 (3), 622–633. doi:10.1016/j.cell.2015.03.022
Chen, X., Li, M., wong, Z. G., Orser, B. A., Macdonald, J. F., and Lu, W. Y. (2011). An anti-coagulation agent Futhan preferentially targets GABA (A) receptors in lungepithelia: implication in treating asthma. Int. J. Physiol. Pathophysiol. Pharmacol. 3 (4), 249–256.
Choi, B. S. (2021). Eosinophils and childhood asthma. Clin. Experimental Pediatrics 64 (2), 60–67. doi:10.3345/cep.2020.00717
Choi, Y., Le Pham, D., Lee, D. H., Lee, S. H., Kim, S. H., and Park, H. S. (2018). Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma. Exp. Molecular Medicine 50 (8), 1–8. doi:10.1038/s12276-018-0136-8
Costello, R. W., Jacoby, D. B., and Fryer, A. D. (1998). Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity. Thorax 53 (7), 613–618. doi:10.1136/thx.53.7.613
Cutz, E., Pan, J., Yeger, H., Domnik, N. J., and Fisher, J. T. (2013). Recent advances and contraversies on the role of pulmonary neuroepithelial bodies as airway sensors[C]//Seminars in cell developmental biology. Acad. Press 24 (1), 40–50. doi:10.1016/j.semcdb.2012.09.003
De Proost, I., Pintelon, I., Brouns, I., Kroese, A. B. A., Riccardi, D., Kemp, P. J., et al. (2008). Functional live cell imaging of the pulmonary neuroepithelial body microenvironment. Am. Journal Respiratory Cell Molecular Biology 39 (2), 180–189. doi:10.1165/rcmb.2008-0011OC
Dilasser, F., Rose, L., Hassoun, D., Klein, M., Rousselle, M., Brosseau, C., et al. (2021). Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. Thorax 76 (4), 326–334. doi:10.1136/thoraxjnl-2020-216271
Drake, M. G., Scott, G. D., Blum, E. D., Lebold, K. M., Nie, Z., Lee, J. J., et al. (2018a). Eosinophils increase airway sensory nerve density in mice and in human asthma. Sci. Translational Medicine 10 (457), eaar8477. doi:10.1126/scitranslmed.aar8477
Drake, M. G., Lebold, K. M., Roth-Carter, Q. R., Pincus, A. B., Blum, E. D., Proskocil, B. J., et al. (2018b). Eosinophil and airway nerve interactions in asthma. J. Leukocyte Biology 104 (1), 61–67. doi:10.1002/JLB.3MR1117-426R
D’Agostino, B., Sgambato, M., Esposito, R., and Spaziano, G. (2019). N/OFQ-NOP system and airways. Handb. Exp. Pharmacol. 254, 313–322. doi:10.1007/164_2018_202
D’Amato, M., Pastore, D., Lupia, C., Candia, C., Bruni, A., Garofalo, E., et al. (2025). Biologic therapy in severe asthma: a phenotype-driven and targeted approach. J. Clin. Med. 14 (13), 4749. doi:10.3390/jcm14134749
El-Baz, L. M. F., Elaidy, S. M., Hafez, H. S., and Shoukry, N. M. (2022). Vismodegib, a sonic hedgehog signalling blockade, ameliorates ovalbumin and ovalbumin/lipopolysaccharide-induced airway inflammation and asthma phenotypical models. Life Sci. 310, 121119. doi:10.1016/j.lfs.2022.121119
Fahy, J. V. (2002). Goblet cell and mucin gene abnormalities in asthma. Chest 122 (6), 320S–326S. doi:10.1378/chest.122.6_suppl.320s
Feldman, M. B., Wood, M., Lapey, A., and Mou, H. (2019). SMAD signaling restricts mucous cell differentiation in human airway epithelium. Am. Journal Respiratory Cell Molecular Biology 61 (3), 322–331. doi:10.1165/rcmb.2018-0326OC
Feng, K. N., Meng, P., Zou, X. L., Zhang, M., Li, H. K., Yang, H. L., et al. (2022). IL-37 protects against airway remodeling by reversing bronchial epithelial–mesenchymal transition via IL-24 signaling pathway in chronic asthma. Respir. Res. 23 (1), 244. doi:10.1186/s12931-022-02167-7
Feng, X., Xue, Y., Bao, R., Chen, S., Yang, H., Xie, F., et al. (2025). Disruption of the vagal TRPA1-Pulmonary neuroendocrine cell axis reduces asthma severity. Allergy 80, 1715–1736. doi:10.1111/all.16599
Flanagan, T. W., Sebastian, M. N., and Nichols, C. D. (2017). Anti-inflammatory effects of serotonin 5-HT2A receptor activation in ovalbumin-induced allergic asthma models. FASEB J. 31, 820.4. doi:10.1096/fasebj.31.1_supplement.820.4
Flanagan, T. W., Foster, T. P., Galbato, T. E., Lum, P. Y., Louie, B., Song, G., et al. (2024). Serotonin-2 receptor agonists produce anti-inflammatory effects through functionally selective mechanisms that involve the suppression of disease-induced arginase 1 expression. ACS Pharmacol. Transl. Sci. 7 (2), 478–492. doi:10.1021/acsptsci.3c00297
Forkuo, G. S., Nieman, A. N., Kodali, R., Zahn, N. M., Li, G., Rashid Roni, M. S., et al. (2018). A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABAA receptors in the lung. Mol. Pharmaceutics 15 (5), 1766–1777. doi:10.1021/acs.molpharmaceut.7b01013
Fryer, A. D., Adamko, D. J., Yost, B. L., and Jacoby, D. B. (1999). Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci. 64 (6-7), 449–455. doi:10.1016/s0024-3205(98)00587-6
Fu, X. W., Nurse, C. A., Wong, V., and Cutz, E. (2002). Hypoxia-induced secretion of serotonin from intact pulmonary neuroepithelial bodies in neonatal rabbit. J. Physiology 539 (2), 503–510. doi:10.1113/jphysiol.2001.013071
Fuhlbrigge, A. L., and Sharma, S. (2025). Unraveling the heterogeneity of asthma: decoding subtypes of asthma. J. Allergy Clin. Immunol. 156, 41–50. doi:10.1016/j.jaci.2025.03.008
Ghosh, S., Alkawadri, T., Hollywood, M. A., Thornbury, K. D., and Sergeant, G. P. (2025). Unravelling the role of post-junctional M2 muscarinic receptors in cholinergic nerve-mediated contractions of airway smooth muscle. Int. J. Mol. Sci. 26 (12), 5455. doi:10.3390/ijms26125455
Gilmour, D. (2015). Epithelial morphogenesis: stage diving with purpose. Dev. Cell 35 (1), 7–8. doi:10.1016/j.devcel.2015.09.025
Gong, R., Liu, X., and Zhao, J. (2023). Electroacupuncture-induced activation of GABAergic system alleviates airway inflammation in asthma model by suppressing TLR4/MyD88/NF-κB signaling pathway. Chin. Med. J. 136 (4), 451–460. doi:10.1097/CM9.0000000000002314
Groneberg, D. A., Quarcoo, D., Frossard, N., and Fischer, A. (2004). Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 59 (11), 1139–1152. doi:10.1111/j.1398-9995.2004.00665.x
He, A., Chen, J., Guan, J., Huang, Y., Xie, H., Chen, H., et al. (2022). Selective eosinophil necroptosis contributes to airway inflammation and remodeling in asthma. Allergy 77 (11), 3456–3459. doi:10.1111/all.15448
Ike, E., Kawano, T., Takahashi, K., and Miyasaka, T. (2023). Calcitonin gene-related peptide receptor antagonist suppresses allergic asthma responses via downregulation of group 2 innate lymphoid cells in mice. Int. Immunopharmacology 122, 110608. doi:10.1016/j.intimp.2023.110608
Imayama, I., Eccles, J. D., Ascoli, C., Kudlaty, E., and Park, G. Y. (2024). Body weight and allergic asthma: a narrative review. J. Clin. Med. 13 (16), 4801. doi:10.3390/jcm13164801
Ito, T., Udaka, N., Okudela, K., Yazawa, T., and Kitamura, H. (2003). Mechanisms of neuroendocrine differentiation in pulmonary neuroendocrine cells and small cell carcinoma. Endocr. Pathology 14, 133–139. doi:10.1385/ep:14:2:133
Ito, T., Udaka, N., Yazawa, T., Okudela, K., Hayashi, H., Sudo, T., et al. (2000). Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development 127 (18), 3913–3921. doi:10.1242/dev.127.18.3913
Jacoby, D. B., Gleich, G. J., and Fryer, A. D. (1993). Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J. Clinical Investigation 91 (4), 1314–1318. doi:10.1172/JCI116331
Jin, Y., Pan, Z., Zhou, J., Wang, K., Zhu, P., Wang, Y., et al. (2024). Hedgehog signaling pathway regulates Th17 cell differentiation in asthma via IL-6/STAT3 signaling. Int. Immunopharmacology 139, 112771. doi:10.1016/j.intimp.2024.112771
Joos, G. F., Germonpre, P. R., and Pauwels, R. A. (2000). Role of tachykinins in asthma. Allergy 55 (4), 321–337. doi:10.1034/j.1398-9995.2000.00112.x
Kabata, H., Moro, K., Koyasu, S., and Asano, K. (2015). Group 2 innate lymphoid cells and asthma. Allergol. Int. 64 (3), 227–234. doi:10.1016/j.alit.2015.03.004
Kelly, V. J., Hibbert, K. A., Kohli, P., Kone, M., Greenblatt, E. E., Venegas, J. G., et al. (2017). Hypoxic pulmonary vasoconstriction does not explain all regional perfusion redistribution in asthma. Am. Journal Respiratory Critical Care Medicine 196 (7), 834–844. doi:10.1164/rccm.201612-2438OC
Kim, E., Wells, B. K., Indralingam, H., Su, Y., Verheyden, J., and Sun, X. (2025). Allergen induces pulmonary neuroendocrine cell hyperplasia in a model of asthma. JCI Insight 10 (13), e187018. doi:10.1172/jci.insight.187018
Kimura, Y., Shinoda, M., Shinkai, M., and Kaneko, T. (2023). Solithromycin inhibits IL-13-induced goblet cell hyperplasia and MUC5AC, CLCA1, and ANO1 in human bronchial epithelial cells. PeerJ 11, e14695. doi:10.7717/peerj.14695
Kuo, C. S., and Krasnow, M. A. (2015). Formation of a neurosensory organ by epithelial cell slithering. Cell 163 (2), 394–405. doi:10.1016/j.cell.2015.09.021
Li, X., and Yang, N. (2023). Exosome miR-223-3p in the bone marrow-derived mesenchymal stem cells alleviates the inflammation and airway remodeling through NLRP3-induced ASC/Caspase-1/GSDMD signaling pathway. Int. Immunopharmacol. 123, 110746. doi:10.1016/j.intimp.2023.110746
Li, M., Wetzel-Strong, S. E., Hua, X., Tilley, S. L., Oswald, E., Krummel, M. F., et al. (2014). Deficiency of RAMP1 attenuates antigen-induced airway hyperresponsiveness in mice. PloS One 9 (7), e102356. doi:10.1371/journal.pone.0102356
Li, M., Zhong, X., and Xu, W. T. (2022). Substance P promotes the progression of bronchial asthma through activating the PI3K/AKT/NF-κB pathway mediated cellular inflammation and pyroptotic cell death in bronchial epithelial cells. Cell Cycle 21 (20), 2179–2191. doi:10.1080/15384101.2022.2092166
Lu, Y., Huang, Y., Li, J., Huang, J., Zhang, L., Feng, J., et al. (2021). Eosinophil extracellular traps drive asthma progression through neuro-immune signals. Nat. Cell Biology 23 (10), 1060–1072. doi:10.1038/s41556-021-00762-2
Lu, X., Tan, Z. X., Yao, Y. X., Li, Z. Y., Zhu, Y. Y., Yang, Q. Q., et al. (2025). Inhaling arsenic aggravates airway hyperreactivity by upregulating PNEC-sourced 5-HT in OVA-induced allergic asthma. Ecotoxicol. Environ. Saf. 290, 117764. doi:10.1016/j.ecoenv.2025.117764
Mann-Nüttel, R., Mandal, S., Armbruster, M., Puttagunta, L., and Forsythe, P. (2024). Human pulmonary neuroendocrine cells respond to house dust mite extract with PAR-1 dependent release of CGRP. Allergy. 80 (4), 976–985. doi:10.1111/all.16416
Matsuyama, T., Machida, K., Mizuno, K., Matsuyama, H., Dotake, Y., Shinmura, M., et al. (2023). The functional role of group 2 innate lymphoid cells in asthma. Biomolecules 13 (6), 893. doi:10.3390/biom13060893
Mattes, J., and Collison, A. (2020). Fetal eosinophils get on the nerves of airways. Early origins of bronchoconstriction. Am. J. Respir. Cell Mol. Biol. 62 (4), 407–408. doi:10.1165/rcmb.2019-0438ED
Matucci, A., Bormioli, S., Nencini, F., Maggi, E., and Vultaggio, A. (2021). The emerging role of type 2 inflammation in asthma. Expert Review Clinical Immunology 17 (1), 63–71. doi:10.1080/1744666x.2020.1860755
McBrien, C. N., and Menzies-Gow, A. (2017). The biology of eosinophils and their role in asthma. Front. Medicine 4, 93. doi:10.3389/fmed.2017.00093
Misaka, S., Aoki, Y., Karaki, S., Kuwahara, A., Mizumoto, T., Onoue, S., et al. (2010). Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides 31 (1), 72–78. doi:10.1016/j.peptides.2009.09.032
Morshed, M., Yousefi, S., Stöckle, C., Simon, H. U., and Simon, D. (2012). Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 67 (9), 1127–1137. doi:10.1111/j.1398-9995.2012.02868.x
Mukherjee, M., Lacy, P., and Ueki, S. (2018). Eosinophil extracellular traps and inflammatory pathologies-untangling the web. Front. Immunol. 9. 2763. doi:10.3389/fimmu.2018.02763
Nau, F. J., Yu, B., Miller, J., Ahlert, T., Cormier, S., and Nichols, C. D. (2012). Serotonin 5-HT2A receptor activation potently inhibits TNF-α mediated inflammation in vivo, and blocks the development of asthma. 26, doi:10.1096/fasebj.26.1_supplement.1120.1
Noguchi, M., Furukawa, K. T., and Morimoto, M. (2020). Pulmonary neuroendocrine cells: physiology, tissue homeostasis and disease. Dis. Models Mechanisms 13 (12), dmm046920. doi:10.1242/dmm.046920
O'Connor, T. M., O'Connell, J., O'Brien, D. I., Goode, T., Bredin, C. P., and Shanahan, F. (2004). The role of substance P in inflammatory disease. J. Cellular Physiology 201 (2), 167–180. doi:10.1002/jcp.20061
Onoue, S., Yamada, S., and Yajima, T. (2007). Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 28 (9), 1640–1650. doi:10.1016/j.peptides.2007.04.009
OrdoñEz, C. L., Khashayar, R., Wong, H. H., Ferrando, R., Wu, R., Hyde, D. M., et al. (2001). Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am. Journal Respiratory Critical Care Medicine 163 (2), 517–523. doi:10.1164/ajrccm.163.2.2004039
Ouadah, Y., Rojas, E. R., Riordan, D. P., Capostagno, S., Kuo, C. S., and Krasnow, M. A. (2019). Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and notch. Cell 179 (2), 403–416. doi:10.1016/j.cell.2019.09.010
Pan, J., Copland, I., Post, M., Yeger, H., and Cutz, E. (2006). Mechanical stretch-induced serotonin release from pulmonary neuroendocrine cells: implications for lung development. Am. J. Physiology-Lung Cell. Mol. Physiology 290 (1), L185–L193. doi:10.1152/ajplung.00167.2005
Pavón-Romero, G. F., Serrano-Pérez, N. H., García-Sánchez, L., Ramírez-Jiménez, F., and Terán, L. M. (2021). Neuroimmune pathophysiology in asthma. Front. Cell Dev. Biol. 9, 663535. doi:10.3389/fcell.2021.663535
Peake, J. L., Reynolds, S. D., Stripp, B. R., Stephens, K. E., and Pinkerton, K. E. (2000). Alteration of pulmonary neuroendocrine cells during epithelial repair of naphthalene-induced airway injury. Am. Journal Pathology 156 (1), 279–286. doi:10.1016/S0002-9440(10)64728-1
Pelaia, C., Crimi, C., Vatrella, A., Tinello, C., Terracciano, R., and Pelaia, G. (2020). Molecular targets for biological therapies of severe asthma. Front. Immunology 11, 603312. doi:10.3389/fimmu.2020.603312
Piao, X., Jiang, S., Wang, J., Wu, J., Xu, W. C., Li, L. Q., et al. (2021). **chuan formula attenuates airway mucus hypersecretion via regulation of the PNEC-GABA-IL13-Muc5ac axis in asthmatic mice. Biomed. Pharmacother. 140, 111746. doi:10.1016/j.biopha.2021.111746
Popko, S. S., Yevtushenko, V. M., and Syrtsov, V. K. (2020). Influence of pulmonary neuroendocrine cells on lung homeostasis. doi:10.14739/2310-1210.2020.4.208411
Possa, S. S., Leick, E. A., Prado, C. M., Martins, M. A., and Tibério, I. F. L. C. (2013). Eosinophilic inflammation in allergic asthma. Front. Pharmacology 4, 46. doi:10.3389/fphar.2013.00046
Qin, L., Yao, Y., Wang, W., Qin, Q., Liu, J., Liu, H., et al. (2024). Airway epithelial overexpressed cathepsin K induces airway remodelling through epithelial–mesenchymal trophic unit activation in asthma. Br. J. Pharmacol. 181 (19), 3700–3716. doi:10.1111/bph.16423
Raby, K. L., Michaeloudes, C., Tonkin, J., Chung, K. F., and Bhavsar, P. K. (2023). Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD. Front. Immunology 14, 1201658. doi:10.3389/fimmu.2023.1201658
Rawlins, E. L., Okubo, T., Xue, Y., Brass, D. M., Auten, R. L., Hasegawa, H., et al. (2009). The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar. Epithelium. Cell Stem Cell 4 (6), 525–534. doi:10.1016/j.stem.2009.04.002
Reynolds, S. D., Giangreco, A., Power, J. H. T., and Stripp, B. R. (2000a). Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. Am. Journal Pathology 156 (1), 269–278. doi:10.1016/S0002-9440(10)64727-X
Reynolds, S. D., Hong, K. U., Giangreco, A., Mango, G. W., Guron, C., Morimoto, Y., et al. (2000b). Conditional clara cell ablation reveals a self-renewing progenitor function of pulmonary neuroendocrine cells. Am. J. Physiology-Lung Cell. Mol. Physiology 278 (6), L1256–L1263. doi:10.1152/ajplung.2000.278.6.L1256
Sahnoon, L., Bajbouj, K., Mahboub, B., Hamoudi, R., and Hamid, Q. (2025). Targeting il-13 and il-4 in asthma: therapeutic implications on airway remodeling in severe asthma. Clin. Rev. Allergy Immunol. 68 (1), 44. doi:10.1007/s12016-025-09045-2
Schuller, H. M., Plummer, I. I. I. H. K., and Jull, B. A. (2003). Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells. Anatomical Rec. Part A Discov. Mol. Cell. Evol. Biol. 270 (1), 51–58. doi:10.1002/ar.a.10019
Seeholzer, L. F., and Julius, D. (2024). Neuroendocrine cells initiate protective upper airway reflexes. Science 384 (6693), 295–301. doi:10.1126/science.adh5483
Shirey, K. A., Lai, W., Sunday, M. E., Cuttitta, F., Blanco, J. C. G., and Vogel, S. N. (2023). Novel neuroendocrine role of γ-aminobutyric acid and gastrin-releasing peptide in the host response to influenza infection. Mucosal Immunology 16 (3), 302–311. doi:10.1016/j.mucimm.2023.03.004
Song, B., Hu, J., Chen, S., and Zhang, Y. (2025). The mechanisms and therapeutic implications of PI3K signaling in airway inflammation and remodeling in asthma. Biol. Targets Ther. 19, 73–86. doi:10.2147/BTT.S497622
Sugita, K., Steer, C. A., Martinez-Gonzalez, I., Altunbulakli, C., Morita, H., Castro-Giner, F., et al. (2018). Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. J. Allergy Clin. Immunol. 141 (1), 300–310. doi:10.1016/j.jaci.2017.02.038
Sui, P., Wiesner, D. L., Xu, J., Zhang, Y., Lee, J., Van Dyken, S., et al. (2018). Pulmonary neuroendocrine cells amplify allergic asthma responses. Science 360 (6393), eaan8546. doi:10.1126/science.aan8546
Sumpter, T., Tkacheva, O., Shufesky, W., Morelli, A., and Larregina, A. (2014). Signaling via neurokinin 1 and 2 receptors exerts opposing effects on mast cell pro-inflammatory and Th2-biasing functions.(HYP3P. 347). J. Immunol. 192 (1_Suppl. ment), 54.5. doi:10.4049/jimmunol.192.supp.54.5
Sun, L., Ren, X., Wang, I. C., Pradhan, A., Zhang, Y., Flood, H. M., et al. (2017). The FOXM1 inhibitor RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. Sci. Signal. 10 (475), eaai8583. doi:10.1126/scisignal.aai8583
Tam, A., Osei, E. T., Cheung, C. Y., Hughes, M., Yang, C. X., McNagny, K. M., et al. (2022). Hedgehog signaling as a therapeutic target for airway remodeling and inflammation in allergic asthma. Cells 11 (19), 3016. doi:10.3390/cells11193016
Thakur, A., Mei, S., Zhang, N., Zhang, K., Taslakjian, B., Lian, J., et al. (2024). Pulmonary neuroendocrine cells: crucial players in respiratory function and airway-nerve communication. Front. Neurosci. 18, 1438188. doi:10.3389/fnins.2024.1438188
Verma, A. K., Manohar, M., Venkateshaiah, S. U., and Mishra, A. (2017). Neuroendocrine cells derived chemokine vasoactive intestinal polypeptide (VIP) in allergic diseases. Cytokine Growth Factor Reviews 38, 37–48. doi:10.1016/j.cytogfr.2017.09.002
Watkins, D. N., Berman, D. M., Burkholder, S. G., Wang, B., Beachy, P. A., and Baylin, S. B. (2003). Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422 (6929), 313–317. doi:10.1038/nature01493
Xu, C., Zou, C., Hussain, M., Shi, W., Shao, Y., Jiang, Z., et al. (2018). High expression of Sonic hedgehog in allergic airway epithelia contributes to goblet cell metaplasia. Mucosal Immunology 11 (5), 1306–1315. doi:10.1038/s41385-018-0033-4
Xiang, Y. Y., Wang, S., Liu, M., Hirota, J. A., Li, J., Ju, W., et al. (2007). A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. Nat. Medicine 13 (7), 862–867. doi:10.1038/nm1604
Xu, J., Yu, H., and Sun, X. (2020). Less is more: rare pulmonary neuroendocrine cells function as critical sensors in lung. Dev. Cell 55 (2), 123–132. doi:10.1016/j.devcel.2020.09.024
Yocum, G. T., Turner, D. L., Danielsson, J., Barajas, M. B., Zhang, Y., Xu, D., et al. (2017). GABAA receptor α4-subunit knockout enhances lung inflammation and airway reactivity in a murine asthma model. Am. J. Physiology-Lung Cell. Mol. Physiology 313 (2), L406–L415. doi:10.1152/ajplung.00107.2017
Youngson, C., Nurse, C., Yeger, H., and Cutz, E. (1993). Oxygen sensing in airway chemoreceptors. Nature 365 (6442), 153–155. doi:10.1038/365153a0
Yu, W., Moninger, T. O., Rector, M. V., Stoltz, D. A., and Welsh, M. J. (2022). Pulmonary neuroendocrine cells sense succinate to stimulate myoepithelial cell contraction. Dev. Cell 57 (18), 2221–2236. e5. doi:10.1016/j.devcel.2022.08.010
Yuan, L., Qin, Q., Yao, Y., Chen, L., Liu, H., Du, X., et al. (2024). Increased expression of cathepsin C in airway epithelia exacerbates airway remodeling in asthma. JCI Insight 9 (22), e181219. doi:10.1172/jci.insight.181219
Zahn, N. M., Huber, A. T., Mikulsky, B. N., Stepanski, M. E., Kehoe, A. S., Li, G., et al. (2019). MIDD 0301–A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression. Basic Clinical Pharmacology Toxicology 125 (1), 75–84. doi:10.1111/bcpt.13206
Zhang, N., Xu, J., Jiang, C., and Lu, S. (2022). Neuro-immune regulation in inflammation and airway remodeling of allergic asthma. Front. Immunol. 13, 894047. doi:10.3389/fimmu.2022.894047
Zhang L., L., Jiang, H., Yang, G., Zhang, J., Yuan, S., Chen, J., et al. (2025). Global, regional and national burden of asthma from 1990 to 2021: a systematic analysis for the global burden of disease study 2021. BMJ Open Respir. Res. 12 (1), e003144. doi:10.1136/bmjresp-2025-003144
Zhang, R., Zhong, Y., Liu, Q., Zhang, M., Wang, D., Li, S., et al. (2025). CGRP alleviates lipopolysaccharide-induced ARDS inflammation via the HIF-1α signaling pathway. Clin. Sci. (Lond) 139 (07), 373–387. doi:10.1042/CS20243170
Glossary
PNECs Pulmonary neuroendocrine cells
ILC2s type 2 innate lymphoid cells
GC Goblet cells
Eos Eosinophils
ICS Inhaled corticosteroids
CGRP Calcitonin gene-related peptide
GABA Gamma-aminobutyric acid
5-HT Serotonin/5-hydroxytryptamine
SP Substance P
NKA Neurokinin A
N/OFQ Nociceptin/orphanin FQ
VIP Vasoactive intestinal peptide
NEBs Neuroepithelial bodies
HPV Hypoxic pulmonary vasoconstriction
DCVs Dense cisternae vesicles
ACh Acetylcholine
Ascl1 Achaete-scute-like protein 1
IL Interleukin
SHH Sonic Hedgehog
PAH Pulmonary hypertension
MUC Mucin
MBP Major basic protein
EETs Eosinophil extracellular traps
TSLP Thymic stromal lymphopoietin
NK-1R Neurokinin-1 receptors
NK-2R Neurokinin-2 receptors
TPH Tryptophan hydroxylase
AI Airway Inflammation
AR Airway Remodelling
AHR Airway Hyper-responsiveness
MEC Myoepithelial Cell
ECs Epithelial Cells
Keywords: asthma, eosinophils, goblet cell, ILC2s, PNECs
Citation: Wang L, Wang H, Yuan Y, Ye W and Fang X (2026) Advances in pulmonary neuroendocrine cells and their cellular interactions in asthma pathogenesis. Front. Pharmacol. 16:1725531. doi: 10.3389/fphar.2025.1725531
Received: 15 October 2025; Accepted: 11 December 2025;
Published: 07 January 2026.
Edited by:
Ahmed Nadeem, King Saud University, Saudi ArabiaReviewed by:
Renan Santo, University of Maryland, United StatesSabita Singh, Indian Institute of Chemical Biology (CSIR), India
Copyright © 2026 Wang, Wang, Yuan, Ye and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Weidong Ye, MTQwMjE2ODQ5MEBxcS5jb20=; Xiangming Fang, ZnhtLmJzaEAxNjMuY29t